🇺🇸 antilymphocyte serum in United States
102 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 102
Most-reported reactions
- Cytomegalovirus Infection — 19 reports (18.63%)
- Lung Infection — 12 reports (11.76%)
- Pyrexia — 12 reports (11.76%)
- Off Label Use — 10 reports (9.8%)
- Leukopenia — 9 reports (8.82%)
- Pathogen Resistance — 9 reports (8.82%)
- Pneumonia Cytomegaloviral — 9 reports (8.82%)
- Renal Failure — 8 reports (7.84%)
- Diarrhoea Infectious — 7 reports (6.86%)
- Escherichia Infection — 7 reports (6.86%)
Other Immunology approved in United States
Frequently asked questions
Is antilymphocyte serum approved in United States?
antilymphocyte serum does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for antilymphocyte serum in United States?
National Heart, Lung, and Blood Institute (NHLBI) is the originator. The local marketing authorisation holder may differ — check the official source linked above.